[1] De Moerlooze L, Spencer-Dene B, Revest JM, et al.An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis[J]. Development, 2000, 127(3): 483-492. [2] Kang H, Kiess A, Chung CH.Emerging biomarkers in head and neck cancer in the era of genomics[J]. Nat Rev Clin Oncol, 2015, 12(1): 11-26. [3] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424 [4] Gould SE, Junttila MR, de Sauvage FJ. Translational value of mouse models in oncology drug development[J]. Nat Med, 2015, 21(5): 431-439. [5] de Visscher SA, Witjes MJ, van der Vegt B, et al. Localization of liposomal mTHPC formulations within normal epithelium, dysplastic tissue, and carcinoma of oral epithelium in the 4NQO-carcinogenesis rat model[J]. Lasers Surg Med, 2013, 45(10): 668-678. [6] Miki K, Orita Y, Gion Y, et al.Tumor-associated macrophages in the development of 4-nitroquinoline-1-oxide-induced tongue squamous cell carcinoma in a mouse model[J]. Oncology, 2017, 93(3): 204-212. [7] Young MR.Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer[J]. J Immunother, 2008, 31(2): 148-156. [8] Tseng SH, Yang CC, Yu EH, et al.K14-EGFP-miR-31 transgenic mice have high susceptibility to chemical-induced squamous cell tumorigenesis that is associating with Ku80 repression[J]. Int J Cancer, 2015, 136(6): 1263-1275. [9] Miki K, Orita Y, Gion Y, et al.Regulatory T cells function at the early stage of tumor progression in a mouse model of tongue squamous cell carcinoma[J]. Cancer Immunol Immunother, 2016, 65(11): 1401-1410. [10] Ohne M, Satoh T, Yamada S, et al.Experimental tongue carcinoma of rats induced by oral administration of 4-nitroquinoline 1-oxide (4NQO) in drinking water[J]. Oral Surg Oral Med Oral Pathol, 1985, 59(6): 600-607. [11] Hawkins BL, Heniford BW, Ackermann DM, et al.4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma[J]. Head Neck, 1994, 16(5): 424-432. [12] Makita H, Tanaka T, Fujitsuka H, et al.Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin[J]. Cancer Res, 1996, 56(21): 4904-4909. [13] Bi Y, Deng J, Murry DJ, et al.A whole-body physiologically based pharmacokinetic model of gefitinib in mice and scale-up to humans[J]. AAPS J, 2016, 18(1): 228-238. [14] Olson B, Li Y, Lin Y, et al.Mouse models for cancer immunotherapy research[J]. Cancer Discov, 2018, 8(11): 1358-1365. [15] Nagaya T, Nakamura Y, Okuyama S, et al.Syngeneic mouse models of oral cancer are effectively targeted by anti-CD44-based NIR-PIT[J]. Mol Cancer Res, 2017, 15(12): 1667-1677. [16] Topalian SL, Taube JM, Anders RA, et al.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16(5):275-287. [17] Rothschild U, Muller L, Lechner A, et al.Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions[J]. Swiss Med Wkly, 2018, 148: w14625. [18] Yang Y.Cancer immunotherapy: harnessing the immune system to battle cancer[J]. J Clin Invest, 2015, 125(9): 3335-3337. |